|Day Low/High||31.81 / 33.38|
|52 Wk Low/High||8.00 / 41.97|
The news that Translarna will remain on the European market for at least five more years sent PTC Therapeutics shares soaring.
Sarepta Therapeutics (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, announced today that it is scheduled to present at the Credit Suisse 25 th Annual Healthcare Conference...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, granted equity awards on October 31, 2016, that were previously approved by the Compensation Committee of...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, today reported financial results for the three and nine months ended September 30, 2016.
Microsoft released upgrades and products Wednesday including "Surface Studio" for artists. Bill Gates, Microsoft's Co-Founder, appears below with an early computer running the Paint program, the first of its kind.
More about Vertex' Debbie Downer gene, Biogen's Alzheimer's spin and Sarepta caught in drug launch purgatory.
Jim Cramer likes YUM; says STZ is more appetizing than MNST
Index funds are great, Jim Cramer says, but he encourages investors to do some smart stock picking.
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, will report third quarter 2016 financial results before the NASDAQ Global Market opens...
The trading action remains quite tedious, though there are short-term opportunities out there.
On Monday, PTC said the U.S. Food and Drug Administration denied an appeal of the Translarna refuse-to-file letter issued last February.
Are the Baker Brothers selling Seattle Genetics? Biomarin CEO throws shade on Sarepta. TG Therapeutics management adds to its credibility problem.
You have to dig below the surface and develop a feel for what stocks are leading.
Although Anthem (ANTM) labeled Sarepta's (SRPT) Duchenne muscular drug as 'not medically necessary,' it doesn't mean the insurer won't offer coverage of the treatment, Baird analysts say.
Anthem (ANTM) said today that it doesn't consider Sarepta's (SRPT) Duchenne muscular dystrophy drug to be 'medically necessary,' as it's demonstrated few clinical benefits.
Equities are holding up well, despite concerns that good economic news increases the chances of a rate hike.
SeaDrill's chairman and top shareholder seems willing to lend a hand to keep the company's leverage in check.
Sarepta Therapeutics' (SRPT) multi-country licensing deal with Summit Therapeutics (SMMT) makes the company 'attractive' to potential buyers, RBC says.
Sarepta Therapeutics (SRPT) and Summit Therapeutics (SMMT) signed an exclusive agreement on Tuesday allowing Sarepta to license Summit's DMD drugs in several countries.
Summit Therapetuics shares skyrocketed Tuesday on word that it has entered into an exclusive licensing agreement with drugmaker Sarepta Therapeutics.
Cramer says Eaton is heading higher and is taking Flex over Brooks Automation.
Next week brings earnings and more on Deutsche Bank, Cramer says.
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company ("Catabasis"), and Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced the first patient dosed in the phase III clinical trial of SRP-4045 and SRP-4053 in patients with Duchenne...
We are seeing lower lows in the indices as I write.
Sarepta Therapeutics' (SRPT) stock price target was increased at JMP Securities and RBC Capital on Wednesday due to the potential of Exondys, its Duchenne muscular dystrophy drug.
If the market is looking to correct, election worries are a convenient excuse.